Free Trial

Lineage Cell Therapeutics (LCTX) News Today

Lineage Cell Therapeutics logo
$0.48 -0.02 (-3.23%)
As of 11:42 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Lineage Cell Therapeutics, Inc. stock logo
B. Riley Forecasts Lineage Cell Therapeutics Q1 Earnings
Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) - Equities researchers at B. Riley issued their Q1 2025 earnings per share estimates for shares of Lineage Cell Therapeutics in a note issued to investors on Thursday, March 13th. B. Riley analyst M. Mamtani expects that the compan
Lineage Cell Therapeutics, Inc. stock logo
B. Riley Issues Pessimistic Forecast for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price
B. Riley reduced their price target on Lineage Cell Therapeutics from $4.00 to $3.00 and set a "buy" rating for the company in a report on Friday.
Lineage Cell Therapeutics, Inc. stock logo
HC Wainwright Weighs in on Lineage Cell Therapeutics Q1 Earnings
Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) - Analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Lineage Cell Therapeutics in a report released on Tuesday, March 11th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnin
Lineage Cell Therapeutics, Inc. stock logo
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives Buy Rating from HC Wainwright
HC Wainwright reissued a "buy" rating and set a $9.00 price objective on shares of Lineage Cell Therapeutics in a research report on Tuesday.
Lineage Cell Therapeutics, Inc. stock logo
D. Boral Capital Reaffirms Buy Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)
D. Boral Capital reissued a "buy" rating and set a $2.00 price objective on shares of Lineage Cell Therapeutics in a report on Tuesday.
Lineage Cell Therapeutics, Inc. stock logo
Lineage Cell Therapeutics (LCTX) to Release Earnings on Thursday
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports.
Lineage Cell Therapeutics, Inc. stock logo
Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Short Interest Update
Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Get Free Report) was the target of a large drop in short interest in January. As of January 31st, there was short interest totalling 21,300,000 shares, a drop of 21.4% from the January 15th total of 27,110,000 shares. Based on an average trading volume of 2,560,000 shares, the days-to-cover ratio is presently 8.3 days.
Lineage Cell Therapeutics, Inc. stock logo
HC Wainwright Reaffirms Buy Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)
HC Wainwright reissued a "buy" rating and set a $9.00 target price on shares of Lineage Cell Therapeutics in a report on Tuesday.
Lineage Cell Therapeutics initiates study of OPC1 for spinal injury
Lineage Cell Therapeutics, Inc. stock logo
D. Boral Capital Has Lowered Expectations for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price
D. Boral Capital cut their target price on Lineage Cell Therapeutics from $3.00 to $2.00 and set a "buy" rating on the stock in a research note on Tuesday.
Insiders Are Scooping Up These 5 Stocks Now
Lineage Cell Therapeutics, Inc. stock logo
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Given "Buy" Rating at HC Wainwright
HC Wainwright reaffirmed a "buy" rating and set a $9.00 target price on shares of Lineage Cell Therapeutics in a research report on Friday.
Lineage Cell Therapeutics, Inc. stock logo
Defender Capital LLC. Increases Stock Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)
Defender Capital LLC. lifted its holdings in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) by 19.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,963,348 shares
Lineage Cell Therapeutics, Inc. stock logo
Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Sees Large Growth in Short Interest
Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Get Free Report) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 26,030,000 shares, an increase of 13.5% from the December 15th total of 22,940,000 shares. Based on an average trading volume of 2,170,000 shares, the days-to-cover ratio is currently 12.0 days.
Lineage Cell Therapeutics, Inc. stock logo
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Given New $3.00 Price Target at Maxim Group
Maxim Group reduced their price target on Lineage Cell Therapeutics from $5.00 to $3.00 and set a "buy" rating on the stock in a research report on Friday.
Lineage Cell Therapeutics Issues Letter to Stockholders
Lineage Cell Therapeutics, Inc. stock logo
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Given "Buy" Rating at D. Boral Capital
D. Boral Capital reaffirmed a "buy" rating and issued a $2.00 target price on shares of Lineage Cell Therapeutics in a research report on Friday.
Lineage Cell Therapeutics, Inc. stock logo
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Shares Down 1% - Here's What Happened
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price Down 1% - Here's Why
Lineage Cell Therapeutics, Inc. (LCTX.TA)
Lineage Cell Therapeutics, Inc. stock logo
Lineage Cell Therapeutics FY2024 EPS Lifted by HC Wainwright
Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) - Analysts at HC Wainwright upped their FY2024 EPS estimates for shares of Lineage Cell Therapeutics in a research note issued to investors on Wednesday, December 4th. HC Wainwright analyst J. Pantginis now anticipates that the com
Lineage Cell Therapeutics, Inc. stock logo
Brian M. Culley Acquires 40,000 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Stock
Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Get Free Report) CEO Brian M. Culley purchased 40,000 shares of the firm's stock in a transaction on Thursday, November 21st. The stock was bought at an average cost of $0.60 per share, for a total transaction of $24,000.00. Following the completion of the purchase, the chief executive officer now directly owns 194,842 shares in the company, valued at approximately $116,905.20. This trade represents a 25.83 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.
Lineage Therap Announces $66 Million Direct Offering
Lineage Cell Therapeutics, Inc. stock logo
Lineage Cell Therapeutics FY2024 EPS Raised by Cantor Fitzgerald
Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) - Analysts at Cantor Fitzgerald upped their FY2024 EPS estimates for Lineage Cell Therapeutics in a report issued on Monday, November 18th. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will post earnings per s
Lineage Cell price target lowered to $2 from $3 at D. Boral Capital
Lineage Cell Therapeutics initiated with a Buy at D. Boral Capital
Lineage Cell Therapeutics Reports Q3 2024 Highlights
Lineage Cell Therapeutics's Earnings Outlook
Lineage Cell Therapeutics, Inc. stock logo
Logos Global Management LP Decreases Stock Holdings in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)
Logos Global Management LP cut its stake in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) by 24.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,700,000 shares of the
Lineage Cell Therapeutics, Inc. stock logo
Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) is Raffles Associates LP's 8th Largest Position
Raffles Associates LP increased its stake in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) by 35.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,357,78
MBX Biosciences Inc.
Remove Ads
Get Lineage Cell Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for LCTX and its competitors with MarketBeat's FREE daily newsletter.

LCTX Media Mentions By Week

LCTX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

LCTX
News Sentiment

0.00

0.82

Average
Medical
News Sentiment

LCTX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

LCTX Articles
This Week

0

1

LCTX Articles
Average Week

Remove Ads
Get Lineage Cell Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for LCTX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NYSEAMERICAN:LCTX) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners